EUVIMEDEUVIMED entdecken
Crossref

AI-simulated placebo arms in clinical trials: efficiency should not outpace methodological rigor

Sami Ullah iD, Muhammad Abdullah Gulzar iD, Muhammad Arshman Gill iD, Muhammad Farhan iD

Postgraduate Medical Journal · 08.06.2026

DOI: 10.1093/postmj/qgag076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Postgraduate Medical Journal, online erschienen am 08.06.2026. Verfasst von Sami Ullah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Services Institute of Medical Sciences, Jail Road, Shadman 1, Lahore 54000, Punjab, Pakistan. Die Arbeit nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor, We read with great interest the article by Gautam et al., who discuss the feasibility of using artificial intelligence to simulate placebo arms in randomized clinical trials [1]. The article is timely, thought provoking, and clinically relevant, because it addresses genuine challenges in contemporary trial conduct, including recruitment burden, cost, exposure to placebo or sham interventions, and the need for more efficient evidence generation. The authors should be commended for presenting a forward looking approach that may stimulate important discussion on how artificial intelligence can support clinical research without weakening patient centered trial design. The central concern is that efficiency should not be mistaken for evidentiary equivalence. A contemporaneous placebo arm is not only a logistical component of a trial; it is the mechanism through which randomization protects against both measured and unmeasured confounding. Once a placebo group is replaced, reduced, or materially down weighted, the credibility of the comparison depends on assumptions about source data comparability, disease stability, index date alignment, outcome ascertainment, missingness, and model calibration. Regulatory guidance on external controls has consistently emphasized caution, particularly when disease course is variable, endpoints are subjective, or expected treatment effects are modest [2–4].

Autor:innen und Institutionen

  • Department of Medicine, Services Institute of Medical Sciences, Jail Road, Shadman 1, Lahore 54000, Punjab, Pakistan.

ORCID-Profile: Sami Ullah, Muhammad Abdullah Gulzar, Muhammad Arshman Gill, Muhammad Farhan

Zitieren

APA

Ullah, S., Gulzar, M. A., Gill, M. A., & Farhan, M. (2026). AI-simulated placebo arms in clinical trials: efficiency should not outpace methodological rigor. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgag076

Vancouver

Ullah S, Gulzar MA, Gill MA, Farhan M. AI-simulated placebo arms in clinical trials: efficiency should not outpace methodological rigor. Postgraduate Medical Journal. 2026. doi:10.1093/postmj/qgag076

BibTeX
@article{Ullah2026,
  author = {Ullah, Sami and Gulzar, Muhammad Abdullah and Gill, Muhammad Arshman and Farhan, Muhammad},
  title = {AI-simulated placebo arms in clinical trials: efficiency should not outpace methodological rigor},
  journal = {Postgraduate Medical Journal},
  year = {2026},
  doi = {10.1093/postmj/qgag076}
}
Kostenlos starten →